Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. commercializes ophthalmic disease management products in North America, with a portfolio used in dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions and retina diseases. Its recurring news includes financial results and stockholder letters, commercial product updates for therapies such as VEVYE, ILEVRO, IOPIDINE and TRIESENCE, and distribution arrangements supporting U.S. product availability.
Company updates also cover reimbursement and regulatory developments, scientific presentations in ophthalmology, clinical development for label expansion, product launches and capital actions such as senior unsecured notes. Harrow reports through branded ophthalmic pharmaceuticals and ImprimisRx, reflecting both commercial products and specialty ophthalmic medication operations.
Harrow Health, Inc. (NASDAQ: HROW) announced its second quarter 2020 results, reporting a swift recovery post-COVID-19 impact. CEO Mark L. Baum highlighted record-high revenue days in Q3, attributed to effective product formulations and a new partnership with EyePoint Pharmaceuticals to market DEXYCU®. The company anticipates significant catalysts from Eton, Surface, and Melt in the coming months, bolstering optimism for shareholders.
Harrow Health (NASDAQ: HROW) will release its second quarter 2020 financial results on August 10, 2020, following the market close. A conference call is scheduled for 5:00 PM EDT to discuss these results and recent business developments. The press release will also include a link to the second quarter Letter to Stockholders, available on the Investor Relations website. A replay of the conference call will be accessible until September 10, 2020, with a webcast replay available until November 10, 2020.
Harrow Health (NASDAQ: HROW) announced positive findings from a randomized eye study conducted by its subsidiary ImprimisRx. The study compared patient outcomes using a combination eye drop versus individual drops post-cataract surgery. Results showed the combination drop, which includes prednisolone acetate, gatifloxacin, and bromfenac sodium, demonstrated similar health outcomes with unanimous patient preference for ease of use. The study, published in Clinical Ophthalmology, highlights ImprimisRx's commitment to improving patient compliance and satisfaction with ocular treatments.
Harrow Health, Inc. (HROW) announced that Florida's optometrists can now prescribe its Klarity-C formulation, a preservative-free 0.1% cyclosporine emulsion, following recent updates to the state’s Formulary of Topical Ocular Pharmaceutical Agents. This product has already been prescribed across all 50 states. ImprimisRx, a subsidiary of Harrow, emphasizes the affordability and accessibility of its formulations without the complexities of prior authorizations or co-pays. Klarity-C has gained recognition at the ASCRS Annual Meeting for its efficacy in treating dry eye conditions.
Harrow Health, Inc. (NASDAQ: HROW) announced its first quarter 2020 results, highlighting its optimistic outlook as segments of the economy recover. CEO Mark L. Baum expressed confidence in the ImprimisRx team's ability to support physicians and improve health outcomes. The company has seen orders resume as customers re-open. Upcoming catalysts and developments are discussed in the Letter to Stockholders. A conference call is scheduled for today at 5:00 p.m. EDT for investors and analysts to engage with management.
Summary not available.